Viewing nowCombinationDucaforjin 60/5 mg
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Hwanin Pharmaceutical Co., Ltd.

MFDS item code 202300107 · Approved 2023.01.06 · Insurance code 657203980
Treatment of essential hypertension not controlled with fimasartan monotherapy
This medication is used to control the blood pressure of patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with pimasartan potassium.
The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended to take this medicine at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended to adjust the dose of fimasartan; however, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 60/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or this medicine 60/2.5 mg. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Older adults No initial dose adjustment is required for older adults aged 70 years or younger. Patients with renal impairment No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 mg in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.
This drug can cause serious harm to the fetus and newborn, especially in the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in individuals with allergies to its active ingredients or similar substances, pregnant or breastfeeding women, patients on dialysis, patients with moderate to severe liver impairment, and other specific patients. Patients with reduced blood volume or sodium, patients with impaired kidney function, and patients with renovascular hypertension should use this medication cautiously and their condition should be carefully monitored during administration. While taking this medication, side effects such as dizziness, headache, facial swelling, urination disorders, insomnia, and flushing may occur; consultation with a healthcare provider should be sought if any abnormal symptoms arise. Particular caution should be exercised in cases of hypotension or electrolyte imbalance, and if blood pressure drops too low, the patient should be laid down and, if necessary, fluid therapy initiated. This medication can raise serum potassium levels, so patients with heart failure or kidney disease should have their potassium levels regularly checked through blood tests. There may be interactions when used with other antihypertensive agents or specific medications, so it is essential to inform healthcare providers of any current medications. During pregnancy, the drug should be avoided due to serious potential impacts on the fetus. Its use is also not recommended during breastfeeding. The safety and efficacy of this medication in children and adolescents under 18 years have not yet been established. In the elderly, special dosage adjustments are not required, but some elderly individuals may be more sensitive to the medication, so caution is advised. This drug should not be used in patients with moderate to severe liver impairment, and in case of overdose, symptoms such as hypotension and cardiac arrhythmias may occur, requiring immediate medical attention. This drug should be stored out of reach of children, and transferring to another container is not recommended as it can affect the quality.
Dizziness, orthostatic dizziness, headache, facial swelling, peripheral edema, urination disorders, insomnia, flushing, syncope, sedative effects, migraine, dyspepsia, vomiting, nausea, upper abdominal pain, weakness, foreign body sensation, elevated liver enzyme levels, decreased platelet count, increased serum creatine phosphokinase, cough, muscle contraction, musculoskeletal stiffness, itching, localized urticaria, facial flushing, erectile dysfunction, epilepsy, amyotrophic lateral sclerosis, neuropathy, neuronitis, facial paralysis, normal pressure hydrocephalus, spinal stenosis, acute pancreatitis, intestinal obstruction, hemorrhagic duodenal ulcer, appendicitis, hemorrhoids, abdominal pain, intracranial hemorrhage, transient ischemic attack, atherosclerosis, worsening of cerebral infarction, cerebral hemorrhage, liver cancer, colorectal carcinoma, neoplasm of unspecified type, cervical cancer, prostate cancer, acute renal failure, chronic renal failure, kidney stones, pyelonephritis, urinary incontinence, rhinitis, pulmonary interstitial fibrosis, pharyngitis, pneumonia, pulmonary disease, death, exacerbation of low back pain, osteoarthritis, arthrosis, hypoglycemia, hyperkalemia, pulmonary embolism, purpura, bradycardia, atrial fibrillation, coronary artery disease, aortic stenosis, heart failure, hypertension, acute hepatitis, benign pituitary neoplasm, otitis media, uterine prolapse, recurrent cancer, chest pain, weakness, fatigue, pain, weight gain/loss, hypotension, vasculitis, increased tension, sensory impairment, sensory abnormalities, peripheral neuropathy, taste disorder, tremor, extrapyramidal disorder, gynecomastia, changes in bowel habits, dry mouth, gingival hypertrophy, pancreatitis, hyperglycemia, arthralgia, low back pain, muscle cramps, myalgia, leukopenia, thrombocytopenia, cough, dyspnea, rhinitis, hair loss, hyperhidrosis, purpura, skin discoloration, urticaria, toxic epidermal necrolysis, tinnitus, visual disturbances, increased urination frequency, urination disorders, nocturia, hepatitis, jaundice, elevated liver enzyme levels, pruritus, rash, angioedema, erythema multiforme, myocardial infarction, arrhythmia, thoracic pain, hypotension, sinoatrial block, atrioventricular block, abdominal discomfort, precordial pain, diarrhea, loose stools, constipation, skin flushing, maculopapular rash, heaviness, warmth, impaired glucose tolerance, weakness, symptoms of hypotension due to depletion of blood volume and sodium, elevated serum potassium levels, increased serum creatinine, increased blood urea, acute renal failure, shock symptoms, loss of consciousness, dyspnea, severe hypotension, drowsiness, pulmonary edema, pulmonary edema, hypotension, hypotension, hypotension, hypotension
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a closed container that blocks light and kept at a temperature between 1 and 30 degrees Celsius. This ensures effective maintenance of the drug's efficacy and prevents deterioration.
Orange, rounded rectangular film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Hwanin Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.